JAX strives to advance rare disease research and treatment options

For the past six years, the JAX Rare Disease Translational Center has worked with dozens of rare disease foundations to create custom mouse models that represent rare medical conditions, the majority of which present in young children.

In May 2022, JAX appointed Cathleen (Cat) Lutz, Ph.D., M.B.A. as Vice President of the Rare Disease Translational Center, marking an important step forward in its commitment to rare disease research. The expansion positions the Center to play an integral role throughout the entire rare disease odyssey, from diagnosis to research to drug development. The Center also collaborates closely with biotech and pharmaceutical companies to accelerate the path to drug discovery for these debilitating conditions. By taking a more holistic approach, the Center will make a significant impact on the experience of those living with rare diseases. Read more

Related Posts

Maine’s life sciences sector growth could outpace other industries

Maine’s $2.3 billion life sciences sector, which employed close to 10,000 people in 2024, will outpace the growth of many other...

13 January 2025

IDEXX gets wiggle room to buy back more shares

IDEXX Laboratories Inc. (Nasdaq: IDXX), a Westbrook-based maker of veterinary diagnostics and software, has the green light from its board of...

10 December 2024

Maine’s first accredited lab for PFAS testing is expanding to meet demand

NORRIDGEWOCK, Maine — This week, the Biden administration moved to prevent dangerous “forever chemicals” from being released onto the market after a less...

6 December 2024